CORMEDIX INC. ANNOUNCES CMS GRANTS PASS-THROUGH STATUS TO DEFENCATH

CorMedix Inc. Reports SECOND Quarter AND SIX MONTH 2024 Financial Results and Provides Business Update

2024-08-14

CORMEDIX INC. TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON AUGUST 14, 2024

2024-08-07

CORMEDIX INC. ANNOUNCES OUTPATIENT AVAILABILITY OF DEFENCATH

2024-07-03

CORMEDIX INC. RECEIVES FDA FEEDBACK ON POTENTIAL LABEL EXPANSION

2024-06-18

CORMEDIX INC. ANNOUNCES CMS GRANTS PASS-THROUGH STATUS TO DEFENCATH

2024-06-06

CORMEDIX INC. ANNOUNCES COMMERCIAL AGREEMENT WITH TOP TIER DIALYSIS PROVIDER

2024-05-28

CORMEDIX INC. TO PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES

2024-05-10

CORMEDIX INC. REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

2024-05-09

CORMEDIX INC. TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 9, 2024

2024-05-06

CORMEDIX INC. ANNOUNCES CMS GRANTS TDAPA TO DEFENCATH

2024-04-19

CORMEDIX INC. ANNOUNCES U.S. INPATIENT COMMERCIAL AVAILABILITY OF DEFENCATH® (TAUROLIDINE AND HEPARIN)

2024-04-15

CORMEDIX INC. ANNOUNCES ABSTRACTS AT UPCOMING SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA CONFERENCE

2024-04-11

CORMEDIX INC. ANNOUNCES COMMERCIAL AGREEMENT WITH ARC DIALYSIS, LLC

2024-04-08

CORMEDIX INC. TO PRESENT AT THE NEEDHAM ANNUAL HEALTHCARE CONFERENCE

2024-03-27

CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

2024-03-12

CORMEDIX INC. TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MARCH 12, 2024

2024-03-06

CORMEDIX INC. ANNOUNCES COMMERCIAL AND REIMBURSEMENT UPDATES

2024-01-30

CORMEDIX INC. ANNOUNCES COMMERCIAL AND OPERATIONAL UPDATES

2024-01-08

CORMEDIX INC. ANNOUNCES APPPOINTMENT OF CHIEF LEGAL OFFICER

2023-12-15

CORMEDIX INC. ANNOUNCES PARTNERSHIP WITH THE LEAPFROG GROUP

2023-12-04

CORMEDIX INC. ANNOUNCES FDA APPROVAL OF DEFENCATH® TO REDUCE THE INCIDENCE OF CATHETER-RELATED BLOODSTREAM INFECTIONS IN ADULT HEMODIALYSIS PATIENTS

2023-11-15

CORMEDIX INC. REPORTS THIRD QUARTER AND NINE MONTH 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

2023-11-14

CORMEDIX INC. TO REPORT THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON NOVEMBER 14, 2023

2023-11-06

CORMEDIX INC. TO PRESENT AT THE CANTOR FITZGERALD GLOBAL HEALTHCARE CONFERENCE

2023-09-26

CORMEDIX INC. TO PRESENT AT THE H.C. WAINWRIGHT ANNUAL GLOBAL INVESTMENT CONFERENCE

2023-09-06

CORMEDIX INC. ANNOUNCES ISSUANCE OF U.S. PATENT COVERING LEAD PRODUCT DEFENCATH

2023-08-30

CORMEDIX INC. REPORTS SECOND QUARTER AND SIX MONTH 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

2023-08-08

CORMEDIX INC. TO REPORT SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON AUGUST 8, 2023

2023-07-27

CORMEDIX INC. ANNOUNCES PRICING OF $40 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

2023-06-28

CORMEDIX INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE OF RESUBMISSION OF NEW DRUG APPLICATION FOR DEFENCATH

2023-06-21

CORMEDIX INC. ANNOUNCES STRATEGIC INITIATIVE WITH BOSTON MEDICAL CENTER TO REDUCE HEALTH DISPARITIES IN PATIENTS AT RISK FOR BLOODSTREAM INFECTIONS

2023-06-15

CORMEDIX INC. TO PRESENT AT THE JEFFERIES HEALTHCARE CONFERENCE

2023-05-30

CORMEDIX INC. ANNOUNCES RESUBMISSION OF NEW DRUG APPLICATION FOR DEFENCATH

2023-05-16

CORMEDIX INC. TO REPORT FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 15, 2023

2023-05-08

CORMEDIX INC. TO PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES

2023-05-03

CORMEDIX INC. ANNOUNCES NOTICE OF ALLOWANCE FOR U.S. PATENT APPLICATION COVERING LEAD PRODUCT DEFENCATH

2023-05-01

CORMEDIX INC. ANNOUNCES REGULATORY, MANUFACTURING AND REIMBURSEMENT UPDATES

2023-04-26

CORMEDIX INC. ANNOUNCES APPOINTMENT OF ROBERT A. STEWART TO ITS BOARD OF DIRECTORS

2023-04-17

CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

2023-03-30

CORMEDIX INC. ANNOUNCES REGULATORY AND MANUFACTURING UPDATES

2023-03-02

CORMEDIX INC. ANNOUNCES PROMOTIONS IN COMMERCIAL AND TECH OPS

2023-01-18

CORMEDIX INC. ANNOUNCES PRESENTATION AT CONFERENCE SHOWING MORTALITY RISK AND COMPLICATIONS IN PATIENTS EXPERIENCING CATHETER RELATED BLOOD STREAM INFECTIONS

2022-12-06

CORMEDIX INC. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

2022-11-10

CORMEDIX INC. TO REPORT THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON NOVEMBER 10

2022-11-02

CORMEDIX INC. ANNOUNCES ABSTRACT PRESENTATION AT UPCOMING AMERICAN SOCIETY OF NEPHROLOGY CONFERENCE

2022-10-20

CORMEDIX INC. ANNOUNCES CMS REVISION TO NTAP REIMBURSEMENT OF DEFENCATH

2022-09-07

CorMedix Inc. Reports SECOND Quarter AND SIX MONTH 2022 Financial Results and Provides Business Update

2022-08-11

CORMEDIX INC. ANNOUNCES REGULATORY AND MANUFACTURING UPDATES

2022-08-08

CORMEDIX INC. TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON AUGUST 11

2022-08-01

CorMedix to Participate at the JMP Securities Life Sciences Conference

2022-06-08

CorMedix Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

2022-05-12

CORMEDIX INC. ANNOUNCES LEADERSHIP UPDATES AND OPERATIONAL CHANGES

CORMEDIX INC. TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 12

2022-05-03

CORMEDIX INC. ANNOUNCES SCIENTIFIC ADVISORY BOARD TO SUPPORT COMMERCIALIZATION and pipeline development

2022-04-07

CORMEDIX INC. to Present at the 21st Annual Needham Virtual Healthcare Conference

2022-04-04

CORMEDIX INC. REPORTS fourth QUARTER and full year 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

2022-03-29

CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE of RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH

2022-03-28

CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update on March 29

2022-03-22

CORMEDIX INC. ANNOUNCES THE APPOINTMENT OF CHIEF EXECUTIVE OFFICER

2022-03-17

CORMEDIX INC. ANNOUNCES RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH

2022-02-28

CORMEDIX TO PARTICIPATE IN UPCOMING JANUARY CONFERENCES

2022-01-04

CORMEDIX INC. REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

2021-11-09

CorMedix Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9

2021-11-02

CORMEDIX INC. ANNOUNCES ABSTRACTS AT UPCOMING CONFERENCES SHOWING PATIENT OUTCOMES AND ECONOMIC BURDEN OF CRBSI

2021-10-20

CORMEDIX INC. ANNOUNCES EXECUTIVE LEADERSHIP CHANGES

2021-10-04

CORMEDIX INC. ANNOUNCES REGULATORY UPDATE

2021-09-07

CORMEDIX INC. REPORTS SECOND QUARTER AND SIX MONTH 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

2021-08-12

CorMedix Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12

2021-07-28

CorMedix Inc. Completes Sale of $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Program

2021-06-10

CorMedix Inc. to Participate in Fireside Chat at the JMP Securities Life Sciences Conference

2021-06-09

CorMedix Inc. to Present at the Jefferies Virtual Healthcare Conference

2021-05-27

CorMedix Inc. Reports First Quarter 2021 Financial Results and Provides Business Update

2021-05-13

CorMedix Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13

2021-05-05

CORMEDIX INC. TO PARTICIPATE AT THE 7th ANNUAL TRUIST SECURITIES LIFE SCIENCES SUMMIT

2021-04-28

CORMEDIX HAS MEETING WITH FDA ON DEFENCATH CATHETER LOCK SOLUTION NDA

2021-04-14

CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

2021-03-30

CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2020 Financial Results and Provide a Corporate Update on March 30

2021-03-23

CorMedix Approved to Sell $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Program

2021-03-15

CorMedix Inc. to Host Regulatory Update Conference Call

2021-03-08

CORMEDIX RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR DEFENCATH™ CATHETER LOCK SOLUTION

2021-03-01

CORMEDIX INC. TO BEGIN TRADING ON THE NASDAQ STOCK EXCHANGE

2021-01-21

CORMEDIX INC. ANNOUNCES FDA DECISION THAT ADVISORY COMMITTEE MEETING FOR NEW DRUG APPLICATION FOR DEFENCATH IS NOT NEEDED

2020-11-18

CORMEDIX INC. REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

2020-11-05

CorMedix Appoints Greg Duncan to its Board of Directors

2020-11-02

CorMedix Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 5

2020-10-29

CorMedix to Participate in BIO Investor Forum Digital

2020-10-08

Cormedix Appoints Paulo Costa to its Board of Directors

2020-09-17

CorMedix Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

2020-09-09

CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE FOR FILING AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR DEFENCATH

2020-08-31

CORMEDIX INC. REPORTS SECOND QUARTER AND SIX MONTH 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

2020-08-10

CorMedix Inc. to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 10

2020-08-04

CorMedix Announces Pricing of $20M Public Offering of Common Stock

2020-07-28

CorMedix Announces Proposed Public Offering of Common Stock

2020-07-27

CORMEDIX INC. REPORTS SUBMISSION OF DEFENCATH™ NEW DRUG APPLICATION

2020-07-08

CORMEDIX INC. REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

2020-05-11

CORMEDIX INC. ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER

CorMedix Hosting KOL Call on Antimicrobial Resistance, Catheter-Related Bloodstream Infections (CRBSIs), and the Potential for Neutrolin®

2020-05-06

CorMedix Completes Sale of $5.5 Million of NOL Tax Benefits through New Jersey Technology Business Tax Certificate Transfer Program

2020-04-22

CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

2020-03-17

CorMedix Inc. to Report Fourth Quarter 2019 Financial Results and Provide a Corporate Update on March 16

2020-03-06

CORMEDIX APPROVED TO SELL $5.5 MILLION OF NOL TAX BENEFITS THROUGH THE NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY PROGRAM

2020-02-03

CorMedix Inc. Announces FDA Grant of Rolling Review of Neutrolin® New Drug Application

CORMEDIX INC. REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

2019-11-14

CorMedix Inc. Announces a Change to its Senior Leadership

2019-11-06

CORMEDIX COMPLETES SUCCESSFUL CMC INTERACTION WITH THE FDA

2019-10-21

CORMEDIX INC. ANNOUNCES EXERCISES OF OUTSTANDING WARRANTS

2019-09-30

CORMEDIX INC. ANNOUNCES EXCHANGE AGREEMENT WITH ITS LARGEST INVESTOR

2019-08-15

CORMEDIX PRESENTS AT FDA PUBLIC MEETING ON THE LIMITED POPULATION PATHWAY FOR ANTIBACTERIAL AND ANTIFUNGAL DRUGS

2019-07-17

CORMEDIX RECEIVES ENCOURAGING FDA FEEDBACK ON NEUTROLIN® LOCK-IT-100 DATA

2019-07-09

CORMEDIX ANNOUNCES PUBLICATION OF TAUROLIDINE PRE-CLINICAL ONCOLOGY DATA IN “INVESTIGATIONAL NEW DRUGS” JOURNAL

2019-07-08

CorMedix Inc. Set to Join the Russell 2000® Index

2019-06-26

CorMedix Inc. to Ring NYSE Closing Bell on Monday, June 10

2019-06-10

CORMEDIX INC. REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

2019-05-14

CORMEDIX ANNOUNCES PRESENTATION OF LOCK-IT-100 STUDY RESULTS AT NATIONAL KIDNEY FOUNDATION SPRING 2019 MEETING

2019-05-10

CORMEDIX ANNOUNCES ONLINE PRE-CLINICAL ABSTRACT AT THE UPCOMING ANNUAL MEETING OF AMERICAN SOCIETY OF CLINICAL ONCOLOGY

2019-04-22

CORMEDIX COMPLETES SALE OF $5.4 MILLION OF NOL TAX BENEFITS THROUGH NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY PROGRAM

2019-04-17

CORMEDIX NOTIFIED OF COMPLIANCE WITH NYSE AMERICAN LISTING REQUIREMENTS

2019-04-11

CORMEDIX CONFIRMS PREVIOUSLY ANNOUNCED ONE-FOR-FIVE REVERSE STOCK SPLIT

2019-03-25

CORMEDIX INC. ANNOUNCES APPOINTMENT OF PHOEBE MOUNTS AS EXECUTIVE VICE PRESIDENT AND GENERAL COUNSEL

2019-03-21

CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS, ANNOUNCES REVERSE STOCK SPLIT AND PROVIDES BUSINESS UPDATE

2019-03-14

CORMEDIX INC. APPOINTS ALAN W. DUNTON, M.D. TO BOARD OF DIRECTORS

2019-03-04

CORMEDIX INC. ANNOUNCES FDA MEETING UPDATE

2019-02-14

CORMEDIX INC. ANNOUNCES TOPLINE ANALYSIS OF THE FULL DATA SET OF PHASE 3 LOCK-IT-100 STUDY REINFORCES THE INTERIM RESULTS

2019-01-30

CORMEDIX INC. ANNOUNCES HIGHLY STATISTICALLY SIGNIFICANT TOPLINE RESULTS FOR NEUTROLIN® FROM THE INTERIM ANALYSIS OF THE PHASE 3 LOCK-IT-100 STUDY

2019-01-17

CORMEDIX INC. ANNOUNCES RESIGNATION OF MEMBER OF ITS BOARD OF DIRECTORS

CORMEDIX ANNOUNCES CLOSING OF $7.5 MILLION SENIOR SECURED CONVERTIBLE DEBT FINANCING

2019-01-07

CORMEDIX RECEIVES APPROVAL TO SELL $5.4 MILLION OF NOL TAX BENEFITS THROUGH THE NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY PROGRAM

2018-12-10

CORMEDIX INC. REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call today at 4:30 p.m. Eastern Time

2018-11-14

CORMEDIX INC. CLARIFIES THAT NO NEW SHARES ARE BEING ISSUED IN CONNECTION WITH ITS RECENTLY FILED FORM S-3 REGISTRATION STATEMENT

2018-10-18

CorMedix Announces NYSE American Acceptance of Plan to Regain Listing Compliance

2018-08-31

CORMEDIX INC. TO PRESENT AT THE 20TH ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE

2018-08-30

CORMEDIX INC. REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

2018-08-14

CORMEDIX INC. ANNOUNCES POSITIVE RESULTS OF ITS NEUTROLIN® PHASE 3 LOCK-IT-100 STUDY BASED ON RECOMMENDATION BY INDEPENDENT DATA SAFETY MONITORING BOARD

2018-07-25

CORMEDIX INC. COMPLETES REVIEW AND SOURCE VERIFICATION OF PHASE 3 LOCK-IT 100 DATA FOR NEUTROLIN®

2018-06-20

CORMEDIX INC. RECEIVES A CONTINUED LISTING STANDARD NOTICE FROM THE NYSE AMERICAN

2018-06-19

CORMEDIX INC. REPORTS PROGRESS ON LOCK-IT 100 DATA REVIEW AND APPOINTS PAUL CHEW AS CONSULTANT ADVISOR CMO

2018-05-29

CORMEDIX INC. REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

2018-05-15

CorMedix Inc. to Report First Quarter 2018 Financial Results on Tuesday, May 15

2018-05-09

CorMedix Revises Timeline and Announces Changes to Lock-It-100 Study Management

2018-04-27

CORMEDIX INC. REPORTS Fourth QUARTER and Full-year 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

2018-03-19

CorMedix Inc. Provides Update on its Financing Plans in Connection with its Ongoing LOCK-IT 100 Clinical Study

2018-02-27

CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma

2018-02-26

CorMedix Inc. Achieves Target Number of Events in Its LOCK-IT-100 Study of Neutrolin® for Interim Efficacy Analysis

2018-02-20